Develops a bioconjugation platform using Peptide Asparaginyl Ligases (PALs) to engineer and conjugate antibodies and nanobodies with drug payloads, enabling the production of homogeneous antibody-drug conjugates (ADCs) and radiopharmaceuticals for PET imaging. This technology reduces manufacturing inefficiencies, minimizes radioactive waste, and accelerates the development of cancer immunotherapies and precision medicines, ensuring safer and more effective treatments for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional antibody-drug conjugate (ADC) manufacturing processes often result in heterogeneous products with variable drug-to-antibody ratios (DAR), leading to inconsistent efficacy and potential safety concerns. Existing conjugation methods can also be inefficient, generate significant radioactive waste (in the case of radiopharmaceuticals), and may negatively impact the antibody's activity or immunogenicity.
Solution
Singzyme offers a bioconjugation platform leveraging Peptide Asparaginyl Ligases (PALs) to engineer and conjugate antibodies and nanobodies with drug payloads, enabling the production of homogeneous ADCs and radiopharmaceuticals. This enzymatic technology provides site-specific conjugation, ensuring a consistent DAR and minimizing off-target effects. The platform's high conjugation efficiency reduces manufacturing costs and minimizes radioactive waste when producing radiopharmaceuticals for PET imaging. Singzyme's approach results in safer, more effective precision medicines with minimal impact on the antibody's structure and function.
Target Audience
Singzyme serves global pharmaceutical companies and research institutions involved in the development of antibody-drug conjugates, radiopharmaceuticals, and other bioconjugates for cancer immunotherapy and precision medicine.
Features
- Proprietary Peptide Asparaginyl Ligases (PALs) for site-specific and controlled conjugation
- Enables production of homogeneous ADCs with defined drug-to-antibody ratios (DAR)
- Streamlined, one-pot, one-step conjugation process, reducing manufacturing time to as little as 2 hours for ADCs and 5-30 minutes for radiopharmaceuticals
- High conjugation efficiency minimizes payload excess, lowering manufacturing costs
- Minimal footprint on the final product, with only 3 natural amino acids added, reducing potential immunogenicity
- Compatible with various payloads, including small molecule drugs and radioisotopes
- Supports any DAR and dual payload configurations
- Demonstrated reduction in toxicity and kidney retention in animal studies for ADCs and radiolabeled therapeutics (RLTs)